Is TB-500 Legal in Alabama? How to Access It Legally
See the public record for TB-500
At a glance
- What it is / A synthetic fragment of thymosin beta-4, not the full protein [1]
- FDA approval / None; no approved drug contains it [1]
- FDA compounding lists / On none of them [4][5][6]
- Advisory committee / Voted in favor July 23, 2026; advice only [7]
- HHS draft policy / Names TB-500 acetate for injection; not binding [2][3]
- Alabama access / Unconfirmed; the draft federal policy does not settle it
Is TB-500 an approved drug?
No. FDA's July 2026 review found no USP or National Formulary monograph, no FDA-approved drug containing it, no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, and none authorized by the European Medicines Agency [1]. TB-500 is a synthetic, N-acetylated 7-amino-acid fragment (residues 17 to 23, about 889 g/mol) of the 43-amino-acid protein thymosin beta-4. Human studies of full-length thymosin beta-4 do not show that TB-500 works or is safe [1].
What federal compounding rules allow
FDA says a state-licensed pharmacy or physician may compound only from a bulk substance that complies with a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's list of bulk substances that can be used in compounding [6]. TB-500 is none of these. It is in none of the three interim-policy categories (list updated May 14, 2026) and not on the outsourcing facility list (updated March 21, 2025) [1][4][5]. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].
On FDA's safety-risk page TB-500 sits in the nominated-but-withdrawn table. FDA's stated concerns there are that it has not identified any human exposure data and that injectable peptides may pose immunogenicity risk from aggregation and impurities. Removal from category 2 was not a safety finding [8].
The 2026 advisory vote and the HHS draft
FDA staff proposed in July 2026 that neither TB-500 free base nor the acetate be listed. Their reasons were no human data, no evidence of effectiveness for wound healing, immunogenicity risk and existing approved wound treatments [1]. The Pharmacy Compounding Advisory Committee voted in favor of listing it on July 23, 2026 [7]. That advice is not binding, and listing requires rulemaking [7][2].
HHS filed a draft enforcement-discretion policy on October 28, 2026, with publication scheduled for October 30. It names TB-500 among six peptides and covers the acetate form by subcutaneous or intramuscular injection. Its conditions include a single active ingredient, a patient-specific prescription, and an FDA-registered manufacturer with a certificate of analysis. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that meets them. The notice establishes no rights, is not binding, and compounded drugs are not FDA-approved [2][3].
Alabama
The draft HHS policy is federal, is limited to TB-500 acetate by subcutaneous or intramuscular injection under its stated conditions, and does not establish a legal right to obtain TB-500. Whether that pathway is available in Alabama remains unconfirmed [2][3].
Safety and human data
There is no approved dose and no human dosing study. FDA found no article in which TB-500 was given to a human, no nonclinical toxicity studies and no immunogenicity studies [1]. Its adverse-event database search through March 26, 2025 retrieved no TB-500 reports. Its food and supplement complaint system (January 1, 2004 to March 10, 2025) retrieved two cases involving a blended TB-500 and BPC-157 product, with no safety assessment [1]. FDA's BPC-157 review describes a 40-year-old woman who developed widespread skin hyperpigmentation and gum darkening within a week of a research-only BPC-157 plus TB-500 injection product; because it held two peptides, FDA could not tell which caused it [9]. Safety in humans is unknown [1].
Athletes
WADA names "Thymosin-beta4 and its derivatives e.g. TB-500" in S2.3, prohibited at all times, on the 2026 and 2027 Lists [10][11].
Frequently asked questions
Is TB-500 legal in Alabama?
Did the July 2026 committee vote make TB-500 legal?
Has TB-500 been given to a person in a published study?
Is TB-500 allowed in sport?
References
Show all 11 referencesHide references
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.